Robot-Assisted Biopsy Market Research Report, Analysis and Forecast – (2021 – 2028)

Technological Evolution Driving the Robot-Assisted Biopsy Market 

The Robot-Assisted Biopsy Market is undergoing a transformative shift due to rapid advancements in medical robotics. Over the past decade, precision medicine has emerged as a central pillar of diagnostic innovation. Robotics has become integral in offering minimally invasive procedures with superior accuracy and repeatability. For instance, the integration of real-time imaging with robotic-guided interventions has drastically reduced sampling errors during biopsies. This has not only improved diagnostic yield but has also enhanced patient comfort and safety, making robot-assisted biopsies an increasingly preferred option across major healthcare centers. 

As robotic systems become more sophisticated with AI-powered navigation and machine learning algorithms, the Robot-Assisted Biopsy Market continues to expand its footprint across diverse clinical specialties, including oncology, pulmonology, and neurology. Such convergence of technologies is leading to enhanced procedural outcomes and broadening the range of applicable biopsy procedures. 

Rising Cancer Incidence Fueling Demand in the Robot-Assisted Biopsy Market 

One of the most critical factors propelling the Robot-Assisted Biopsy Market is the sharp rise in global cancer incidence. For example, breast, lung, and prostate cancers collectively account for over 40% of all biopsy procedures performed annually. According to Datavagyanik, over 18 million new cancer cases were diagnosed worldwide in 2024, and this number is expected to surpass 22 million by 2030. As early and accurate detection remains a cornerstone of successful treatment, robot-assisted biopsies are playing a pivotal role in reducing false negatives and enabling timely diagnosis. 

The ability of robotic systems to access hard-to-reach lesions, especially in organs like the lungs or pancreas, has led to greater adoption in tertiary care hospitals. This trend significantly boosts the Robot-Assisted Biopsy Market, particularly in North America, Europe, and rapidly developing economies in Asia-Pacific. 

Integration of Imaging Modalities Enhancing Robot-Assisted Biopsy Market Penetration 

Advanced imaging technologies are significantly contributing to the success and accuracy of robot-assisted biopsies. Systems that combine robotic guidance with imaging modalities such as CT, MRI, and ultrasound are becoming standard across modern diagnostic setups. For instance, fusion biopsy techniques—combining MRI with real-time ultrasound—are becoming widely adopted in prostate cancer diagnosis. 

These hybrid technologies are not only improving spatial accuracy but also reducing the number of biopsy passes required, which minimizes complications. As such, the Robot-Assisted Biopsy Market is witnessing increasing investment in multi-modal systems, especially in research-focused medical institutions and private diagnostic chains seeking competitive differentiation through advanced capabilities. 

Increasing Preference for Minimally Invasive Procedures Accelerating Robot-Assisted Biopsy Market Growth 

Minimally invasive procedures are now a dominant trend in global healthcare due to shorter recovery times, reduced hospital stays, and lower complication rates. Robot-assisted biopsies align perfectly with this shift, offering enhanced precision with reduced physical trauma to the patient. For example, robotic systems used in lung biopsies can navigate complex airway structures more effectively than manual techniques, reducing the incidence of pneumothorax. 

The Robot-Assisted Biopsy Market is benefitting from increasing awareness among patients and practitioners alike about these benefits. Hospitals and outpatient surgery centers are increasingly favoring robotic platforms for soft tissue biopsies, contributing to steady year-over-year growth in installed base and procedural volume. 

Rising Investments and Strategic Partnerships Strengthening the Robot-Assisted Biopsy Market 

Strategic collaborations and increased capital investments are fueling innovation in the Robot-Assisted Biopsy Market. Technology developers are entering partnerships with academic medical centers and imaging device manufacturers to develop next-generation systems. For instance, the trend toward modular robotics platforms that allow customized configurations for different biopsy types is gaining momentum. 

Datavagyanik highlights a 22% increase in venture funding directed towards robotic diagnostic technologies in 2024, underscoring the market’s strong investor confidence. Start-ups are especially active in developing compact, AI-enhanced robotic arms for outpatient biopsy procedures. This wave of investment is expected to significantly enhance the commercial viability and geographic reach of the Robot-Assisted Biopsy Market. 

Expanding Applications Beyond Oncology Boosting the Robot-Assisted Biopsy Market 

Although oncology remains the primary driver, the Robot-Assisted Biopsy Market is expanding into non-oncological domains as well. Neurological conditions such as epilepsy and Parkinson’s disease now often require stereotactic brain biopsies to guide therapeutic decisions. Robotic systems provide the sub-millimeter accuracy necessary for such delicate interventions. 

Similarly, liver and kidney biopsies—traditionally performed using free-hand ultrasound—are increasingly being guided using robotic arms, particularly in obese patients or those with complex anatomical structures. This broadening of clinical applications is helping to diversify revenue streams and reduce dependency on cancer diagnostics alone, thereby making the Robot-Assisted Biopsy Market more resilient and dynamic. 

Robot-Assisted Biopsy Market Size Expanding with Infrastructure Modernization 

Hospital infrastructure modernization is playing a substantial role in scaling the Robot-Assisted Biopsy Market size. With many healthcare facilities integrating smart operation theatres and hybrid diagnostic suites, the demand for interoperable robotic systems is surging. For example, leading hospital networks are adopting integrated systems that combine robotic arms with PACS, RIS, and EHR platforms to streamline workflow and documentation. 

Datavagyanik reports that the Robot-Assisted Biopsy Market size crossed the USD 1.8 billion mark in 2024 and is projected to grow at a CAGR of over 13% during the next five years. This growth is being driven by a combination of equipment upgrades, rising procedural volumes, and increased reimbursement coverage for robotic procedures in several high-income countries. 

Regulatory Support and Reimbursement Reforms Supporting the Robot-Assisted Biopsy Market 

Favorable regulatory frameworks and evolving reimbursement guidelines are reinforcing the commercial viability of the Robot-Assisted Biopsy Market. For instance, streamlined FDA approvals for robotic diagnostic devices are accelerating time-to-market for innovative platforms. Additionally, procedure-specific reimbursement codes are now being introduced in multiple countries to cover robot-assisted biopsies, particularly in high-risk or anatomically complex cases. 

These developments are not only encouraging greater physician adoption but also providing hospitals with the financial incentive to invest in robotic infrastructure. This policy-driven momentum is likely to play a critical role in expanding the Robot-Assisted Biopsy Market over the coming decade. 

Emerging Markets Gaining Momentum in the Robot-Assisted Biopsy Market 

While North America and Europe currently dominate, emerging economies in Asia-Pacific and Latin America are catching up quickly in terms of adoption. Countries like China, India, and Brazil are investing heavily in tertiary care infrastructure and medical robotics. For instance, tertiary cancer centers in urban India have started deploying robotic systems for both therapeutic and diagnostic use, including biopsies. 

This regional expansion is helping to diversify the global footprint of the Robot-Assisted Biopsy Market and driving competition among manufacturers to deliver cost-effective, scalable solutions. Local manufacturing initiatives and skill development programs are also contributing to ecosystem growth, further fueling market penetration. 

Customization and Portability Creating New Opportunities in the Robot-Assisted Biopsy Market 

The need for flexibility in clinical environments is pushing manufacturers to design compact and portable robotic systems. Mobile platforms with plug-and-play modules are now enabling smaller diagnostic labs and outpatient facilities to perform advanced procedures without the need for massive capital investment or infrastructure overhaul. 

This trend is reshaping the competitive landscape of the Robot-Assisted Biopsy Market, opening up access to mid-tier healthcare providers. It also paves the way for potential adoption in remote and rural locations through tele-robotic systems and cloud-connected diagnostics, thereby extending the reach of high-precision biopsy capabilities to underserved populations. 

 

“Track Country-wise Robot-Assisted Biopsy Production and Demand through our Database”

• • • Robot-Assisted Biopsy sales volume database for 29+ countries worldwide

 

North America Maintaining Leadership in the Robot-Assisted Biopsy Market 

North America continues to dominate the Robot-Assisted Biopsy Market, driven by well-established healthcare infrastructure, high adoption of advanced medical technologies, and strong reimbursement frameworks. For instance, the United States accounts for over 40% of the global demand for robot-assisted biopsy procedures. Datavagyanik estimates that robotic biopsy systems are now installed in over 1,000 hospitals across the country, with annual procedural growth exceeding 12%. 

The region’s leadership is reinforced by the presence of key industry players, active clinical trials, and continuous investment in precision diagnostics. Large hospital networks are actively integrating robotic systems with AI-powered pathology platforms, which significantly increases diagnostic efficiency and throughput. The maturity of robotic adoption in oncology-focused centers further cements North America’s position at the forefront of the Robot-Assisted Biopsy Market. 

Europe Witnessing Steady Expansion in the Robot-Assisted Biopsy Market 

Europe represents the second-largest share of the Robot-Assisted Biopsy Market and continues to experience steady growth, particularly in Germany, the United Kingdom, France, and the Netherlands. For example, leading academic hospitals in Germany have adopted robotic-assisted procedures for both thoracic and abdominal biopsies, contributing to wider adoption across Western Europe. 

Governments in the region are actively funding digital healthcare transformation programs, which include grants and incentives for robotics implementation. Datavagyanik notes that in 2024, the number of robotic biopsy procedures across Europe grew by 10%, with the market expected to maintain this trajectory due to continuous demand from aging populations and rising cancer incidence. 

Additionally, the emphasis on minimally invasive techniques and shorter hospital stays aligns well with the capabilities of robotic biopsy platforms, making them a preferred choice in modern surgical environments across Europe. 

Asia-Pacific Emerging as a High-Growth Region in the Robot-Assisted Biopsy Market 

Asia-Pacific is rapidly emerging as a high-growth region in the Robot-Assisted Biopsy Market. Countries such as China, Japan, South Korea, and India are leading the regional demand, driven by a surge in cancer diagnoses and increasing investments in high-tech hospital infrastructure. For instance, China has seen a 15% increase in robotic biopsy installations year-over-year, fueled by both public healthcare spending and private sector innovation. 

Japan continues to leverage its technological leadership in robotics, and its hospitals are at the forefront of integrating robotic systems with advanced imaging modalities for lung and prostate biopsies. Meanwhile, India is seeing growing adoption in tier-1 cities, especially in oncology centers catering to large patient volumes. 

Datavagyanik highlights that Asia-Pacific will contribute over 28% of the incremental growth in the Robot-Assisted Biopsy Market over the next five years, with procedural volumes expected to grow at a CAGR of 16.5%. The region’s relatively untapped markets and large patient population make it a strategic focus for both multinational and domestic manufacturers. 

Latin America and Middle East Showing Nascent but Rising Demand in the Robot-Assisted Biopsy Market 

Although still in the early stages of adoption, Latin America and the Middle East are showing increasing interest in the Robot-Assisted Biopsy Market. In Latin America, Brazil and Mexico are leading the way with high-end private hospitals beginning to offer robot-assisted biopsy procedures, primarily in oncology. 

Similarly, Gulf countries such as the UAE and Saudi Arabia are aggressively upgrading their healthcare infrastructure, and robotic technologies are being introduced as part of national digitization agendas. For instance, tertiary care hospitals in Riyadh and Dubai have begun implementing robotic systems for diagnostic interventions, driven by government-backed initiatives. 

While market penetration in these regions is still low, Datavagyanik identifies strong upside potential, especially as medical tourism and international healthcare partnerships gain traction. Manufacturers targeting these regions are focusing on compact, cost-efficient robotic systems to meet the demand of growing urban healthcare centers. 

Robot-Assisted Biopsy Manufacturing Concentrated in Technologically Advanced Economies 

The Robot-Assisted Biopsy Manufacturing landscape is primarily concentrated in technologically advanced economies such as the United States, Germany, and Japan. These countries host leading robotics firms with strong capabilities in automation, precision engineering, and AI integration. 

For example, robotic systems used in biopsy procedures often require the coordination of electromechanical arms, real-time sensors, and high-resolution imaging. The complex nature of Robot-Assisted Biopsy Manufacturing has led to high entry barriers, favoring firms with extensive R&D capabilities and regulatory expertise. 

Datavagyanik notes that over 70% of global Robot-Assisted Biopsy Manufacturing takes place in the U.S. and Europe, though manufacturing hubs are slowly expanding to Southeast Asia, particularly in countries like Singapore and South Korea, where contract manufacturing of medical devices is gaining momentum. 

Strategic Outsourcing in Robot-Assisted Biopsy Manufacturing to Optimize Costs 

To manage production costs and maintain scalability, several manufacturers are now outsourcing components of Robot-Assisted Biopsy Manufacturing to specialized firms. For instance, precision-milled parts, robotic joints, and embedded sensors are often produced by third-party suppliers in cost-efficient markets before being assembled in facilities closer to end-use markets. 

This modular approach allows for faster production cycles and greater customization based on regional regulatory requirements. As demand grows across different geographic markets, this decentralized manufacturing strategy ensures that supply chains remain agile and responsive to localized needs. 

Datavagyanik observes that contract manufacturing partnerships in the Robot-Assisted Biopsy Manufacturing space increased by 18% in 2024, indicating a strong shift toward operational flexibility and cost optimization. 

Diverse Clinical Applications Driving Segmentation in the Robot-Assisted Biopsy Market 

Segmentation within the Robot-Assisted Biopsy Market is becoming more refined as new clinical applications continue to emerge. The market can be broadly segmented by procedure type, application, end user, and technology. 

By procedure type, the market includes needle-based core biopsies, fine-needle aspiration biopsies, and excisional biopsies. For instance, needle-based robot-assisted lung biopsies are now among the most frequently performed procedures in this category, due to the increasing incidence of pulmonary nodules and lung cancer. 

By application, oncology remains the dominant segment, but neurology and nephrology are growing at a faster pace. In brain biopsies, robotic assistance is critical to ensuring accuracy in stereotactic interventions. Similarly, robot-assisted kidney biopsies are witnessing increased adoption in transplant centers and nephrology departments dealing with complex cases. 

By end user, hospitals continue to lead demand, but specialty diagnostic centers and ambulatory surgical centers are showing faster growth. Their need for compact and efficient robotic systems aligns with trends in outpatient diagnostics. 

By technology, the Robot-Assisted Biopsy Market is increasingly segmented into systems integrated with AI, 3D imaging, and navigation software. This technological differentiation is now a key driver in purchasing decisions, especially for high-volume centers that prioritize speed, accuracy, and workflow efficiency. 

Price Trends Reflecting Technology Intensity in the Robot-Assisted Biopsy Market 

Pricing dynamics in the Robot-Assisted Biopsy Market are heavily influenced by the complexity of systems and the level of integration with imaging and data analytics platforms. High-end robotic biopsy systems designed for hospitals with advanced imaging capabilities command premium prices, often exceeding USD 500,000 per unit. 

On the other hand, portable or semi-automated systems targeted at outpatient and mid-tier facilities are priced more competitively, in the range of USD 100,000 to USD 250,000. For example, robotic arms optimized for prostate or breast biopsies with ultrasound guidance tend to fall in this bracket. 

Datavagyanik indicates that pricing in the Robot-Assisted Biopsy Market remains stable but is expected to moderate slightly as competition increases and manufacturing scale improves. Innovations in design-for-manufacturing and component standardization are expected to reduce unit costs over the next five years. 

Value-Based Pricing Models Gaining Popularity in the Robot-Assisted Biopsy Market 

Healthcare systems are increasingly adopting value-based procurement strategies, and the Robot-Assisted Biopsy Market is responding with flexible pricing models. For instance, leasing models, pay-per-use contracts, and bundled services that include training and maintenance are becoming more common. 

These models are particularly appealing to mid-sized facilities and emerging market hospitals that face capital budget constraints. As a result, manufacturers are adjusting their pricing strategies to focus on lifetime value rather than one-time sales, allowing for greater market penetration without compromising profitability. 

This shift is also fostering greater long-term relationships between providers and vendors, enabling faster adoption of software upgrades, procedural analytics, and remote diagnostics that enhance the capabilities of installed systems. 

 

“Robot-Assisted Biopsy Manufacturing Database”

• • • Robot-Assisted Biopsy top manufacturers market share for 29+ manufacturers
    • Top 9 manufacturers and top 19 manufacturers of Robot-Assisted Biopsy in North America, Europe, Asia Pacific
    • Robot-Assisted Biopsy sales dashboard, Robot-Assisted Biopsy sales data in excel format

 

Leading Manufacturers in the Robot-Assisted Biopsy Market 

The Robot-Assisted Biopsy Market is characterized by a competitive landscape with several key players driving innovation and market growth. Among the top manufacturers are: 

Intuitive Surgical: A pioneer in robotic surgery, Intuitive Surgical offers the Ion endoluminal system, designed for minimally invasive lung biopsies. The Ion system utilizes shape-sensing technology to navigate to peripheral lung nodules, enhancing diagnostic accuracy. 

Johnson & Johnson MedTech: Through its MONARCH platform, Johnson & Johnson provides a robotic-assisted bronchoscopy system that allows for precise navigation and biopsy of lung nodules. The MONARCH system integrates advanced imaging and robotic technology to improve diagnostic yield. 

Medtronic: Medtronic’s Hugo™ robotic-assisted surgery system is a versatile platform that supports various procedures, including biopsies. The system’s modular design and advanced visualization capabilities facilitate precise tissue sampling. 

Brainlab: Specializing in neurosurgical applications, Brainlab’s Cirq® robotic alignment module assists in cranial biopsies by providing accurate alignment to predefined trajectories, enhancing the safety and efficacy of the procedure. 

Renishaw: Renishaw’s neuromate® stereotactic robot is designed for neurosurgical procedures, including brain biopsies. The system offers precise electrode positioning, contributing to improved diagnostic outcomes. 

Auris Health (a subsidiary of Ethicon): Auris Health’s MONARCH™ platform, distinct from Johnson & Johnson’s system, focuses on robotic bronchoscopy for lung biopsies. The platform combines robotic technology with advanced endoscopic visualization. 

Aimooe Technology and BEC Medical: These companies offer robotic systems for various biopsy procedures, contributing to the diversification and accessibility of robotic biopsy technologies. 

Market Share Distribution Among Manufacturers 

The Robot-Assisted Biopsy Market exhibits a distribution of market shares among leading manufacturers: 

• Intuitive Surgical holds a significant portion of the market, attributed to its early entry and continuous innovation in robotic systems. 

• Johnson & Johnson MedTech has captured a substantial share through its MONARCH platform, leveraging its extensive healthcare portfolio and global reach. 

• Medtronic is rapidly gaining market share with its Hugo™ system, appealing to a broad range of surgical applications beyond biopsies. 

• Brainlab and Renishaw maintain strong positions in the neurosurgical segment, focusing on specialized applications that require high precision. 

• Auris Health contributes to the market with its focus on pulmonary procedures, addressing the growing demand for lung cancer diagnostics. 

• Emerging players like Aimooe Technology and BEC Medical are expanding their presence, particularly in cost-sensitive markets, by offering affordable robotic biopsy solutions. 

Recent Developments and Industry Trends 

The Robot-Assisted Biopsy Market is dynamic, with several notable developments: 

• FDA Clearance of MONARCH Quest: In March 2025, Johnson & Johnson MedTech announced FDA clearance for its MONARCH Quest system, an enhanced robotic-assisted bronchoscopy platform designed to improve access to peripheral lung nodules. 

• Integration of Imaging and Robotics: Siemens Healthineers and Intuitive Surgical have collaborated to integrate the Cios Spin mobile C-arm with the Ion system, enabling real-time 3D imaging during robotic bronchoscopy procedures. 

• Advancements in Miniaturization: Researchers have developed a tiny, magnetically guided robot capable of navigating the digestive system to perform 3D scans and potentially deliver targeted therapies, representing a significant leap in minimally invasive diagnostics. 

• Expansion into Emerging Markets: Manufacturers are increasingly targeting emerging economies by developing cost-effective robotic biopsy systems, addressing the rising demand for advanced diagnostic tools in these regions. 

• Focus on AI Integration: Companies are investing in artificial intelligence to enhance the capabilities of robotic biopsy systems, including improved lesion detection, trajectory planning, and real-time decision support. 

 

“Robot-Assisted Biopsy Production Data and Robot-Assisted Biopsy Production Trend”

• • • Robot-Assisted Biopsy sales database for historical years, 10 years historical data
    • Robot-Assisted Biopsy sales data and forecast for next 7 years

Key Insights that the Robot-Assisted Biopsy Market analysis report presents are:

• Robot-Assisted Biopsy Market revenue and demand by countries
• Break-down of the Robot-Assisted Biopsy Market in terms of application areas, target customers, and other potential market segments
• Areas that are relatively more potential and are faster growing
• Robot-Assisted Biopsy Market competitive scenario, market share analysis
• Robot-Assisted Biopsy Market business opportunity analysis

Global and Country-Wise Robot-Assisted Biopsy Market Statistics

• Global and Country-Wise Robot-Assisted Biopsy Market Size ($Million) and Forecast – (2021-2028)
• Global and Country-Wise Robot-Assisted Biopsy Market Trend Analysis
• Global and Country-Wise Robot-Assisted Biopsy Market Business Opportunity Assessment